Updates in the Treatment of Secondary AML After the 2024 SOHO Annual Meeting - Episode 5

Factors When Weighing Intensive Chemotherapy vs Other Regimens in Secondary AML

,

James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss factors for picking intensive chemotherapy vs other regimens in acute myeloid leukemia.

Current Time 0:00
Duration 8:32
Loaded: 0%
Stream Type LIVE
Remaining Time 8:32
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
  • en (Main), selected
EP. 1: The Diagnosis and Prevalence of Secondary AML
EP. 2: Defining Intensive Chemotherapy Fitness in AML
EP. 3: Long-Term Data for CPX-351 in Secondary AML
EP. 4: Dose Intensity and Sequencing of Intensive Chemotherapy in Secondary AML
Now Viewing
EP. 5: Factors When Weighing Intensive Chemotherapy vs Other Regimens in Secondary AML
EP. 6: Goals in the Treatment of Secondary AML
EP. 7: The Role of Genetic Profiling in Secondary AML
x